About the SELECT trial SELECT was a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of Wegovy (semaglutide 2.4 mg) versus placebo as an adjunct to standard of care for the prevention of MACE in people with overweight or obesity and established CVD with no prior history of diabetes
You dont have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease
PlexusDx Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R to show how your metabolism responds to GLP-1 therapy
Each of these patents can serve as an independent PTE basis if the underlying product is approved with the new formulation, indication, or manufacturing process
I know that's not technically right but that is the blunt way to think about it
Which GLP is Right for You